+86-28-82633987
ISO ISO
ISO 17025 ISO 17025
usp usp
EN
CN EN

Antifibrosis

Antifibrosis refers to the medical strategies and treatments aimed at preventing, halting, or reversing the process of fibrosis. Fibrosis is the excessive accumulation of extracellular matrix components, primarily collagen, leading to tissue scarring and organ dysfunction. Antifibrotic therapies target various pathways involved in fibrogenesis, offering potential benefits in conditions like pulmonary fibrosis, liver cirrhosis, and kidney disease, by preserving organ structure and function.
Catalog No Product Description CAS No. Purity Structural Formula
BP1372
Tenacissoside H
Tenacissoside H has antitumor activity on esophageal cancer through arresting cell cycle and regulating PI3K/Akt-NF-κB transduction cascade.
191729-45-0 98% Tenacissoside H
BP4855
Isosilybin B
Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, it has anti-prostate cancer (PCA) activity that is mediated via cell cycle arrest and apoptosis induction. Isosilybin B showed inhibitory effect on CYP2C8 activity. It inhibited both monophenolase (IC50 = 1.7-7.6 μM) and diphenolase (IC50 = 12.1-44.9 μM) of tyrosinase.
142796-22-3 98% Isosilybin B